专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010098627A3 PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2010098627A3
公开(公告)日：2011-01-06
申请号：PCT/KR2010001246
申请日：2010-02-26
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE AH RAM , JANG SEOK YOUNG , PARK YUN SANG , LEE NAYOUNG , LEE EUNMI
IPC分类号： A61K9/22 , A61K9/20 , A61K47/30 , A61P35/00
CPC分类号： A61K9/209 , A61K31/436 , A61K31/4706 , A61K31/505 , A61K31/7068 , A61K2300/00
摘要： The present invention relates to a pharmaceutical preparation comprising an immediate-release compartment and an extended-release compartment, wherein said immediate-release compartment and said extended-release compartment each contain different oral anticancer drugs as active ingredients. The pharmaceutical preparation of the present invention is advantageous in that drug interactions and side effects of oral anticancer drugs can be minimized, and the administration of the pharmaceutical preparation can be easily performed.
摘要翻译：本发明涉及包含立即释放室和延长释放室的药物制剂，其中所述立即释放室和所述延长释放室各自含有不同的口服抗癌药物作为活性成分。本发明的药物制剂的优点在于能够使口服抗癌药物的药物相互作用和副作用最小化，能容易地进行药物制剂的给药。

2. 发明申请

WO2010082785A3 ORAL PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：口服药物组合物
公开(公告)号：WO2010082785A3
公开(公告)日：2010-11-25
申请号：PCT/KR2010000268
申请日：2010-01-15
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
IPC分类号： A61K31/44 , A61K9/22 , A61K31/401 , A61K31/505 , A61P1/00
CPC分类号： A61K31/505 , A61K9/20 , A61K31/401 , A61K31/44
摘要： Provided is an oral pharmaceutical composition comprising: a drug which is metabolised in the liver and a liver protectant. The composition of the present invention can prevent or alleviate drug-induced hepatotoxicity following the administration of a drug which is metabolised in the liver.
摘要翻译：提供一种口服药物组合物，其包含：在肝脏中代谢的药物和肝保护剂。本发明的组合物可以在施用在肝脏中代谢的药物后，预防或缓解药物诱发的肝毒性。

3. 发明申请

WO2010047559A3 SUSTAINED-RELEASE PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：持续释放药物制剂
公开(公告)号：WO2010047559A3
公开(公告)日：2010-07-29
申请号：PCT/KR2009006157
申请日：2009-10-23
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , JANG SEOK YOUNG , LEE SANG JU
IPC分类号： A61K9/52 , A61K9/14 , A61K9/24 , A61K31/138 , A61K31/192
CPC分类号： A61K9/20
摘要： The present invention relates to sustained-release pharmaceutical formulations comprising beta-adrenergic blockers and HMG-CoA reductase inhibitors. The pharmaceutical formulations of the present invention are more effective, and may reduce side effects when the beta-adrenergic blockers and HMG-CoA reductase inhibitors are individually and simultaneously taken as a single formulation. The pharmaceutical formulations of the present invention are effective for treating hypertension in patients with complex diseases such as hyperlipidemia, coronary artery disease, etc. The pharmaceutical formulations of the present invention are also effective for preventing complications developed from the abovementioned diseases, and make it easy to give administration instructions to patients.
摘要翻译：本发明涉及包含β-肾上腺素能阻断剂和HMG-CoA还原酶抑制剂的持续释放药物制剂。当β-肾上腺素能阻断剂和HMG-CoA还原酶抑制剂单独和同时作为单一制剂使用时，本发明的药物制剂更有效，并且可以减少副作用。本发明的药物制剂对于治疗具有诸如高脂血症，冠状动脉疾病等复杂疾病的患者的高血压是有效的。本发明的药物制剂对于预防由上述疾病产生的并发症也是有效的，并且使其容易向患者提供管理指导。

4. 发明申请

WO2009125987A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶类钙通道阻滞剂的延长释放室和具有血管紧张素-2受体阻断剂的立即释放室的药物制剂。本发明提供了药物制剂，其中二氢吡啶类钙通道阻滞剂和血管紧张素-2受体阻断剂分别包含在每个隔室中，并且其释放被控制。由于制剂的每个不同隔室中包含的每种不同药物在不同的时间被释放，所以本发明的药物制剂使药物之间的拮抗作用和副作用最小化并使药物的具体效果最大化。根据本发明的两种药物之间的具体组合，通过与各药物的单次给药或药物的简单组合给药，治疗或预防疾病具有显着的效果。

5. 发明申请

WO2009125987A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶钙通道阻断剂的缓释隔室和具有血管紧张素-2受体阻断剂的速释隔室的药物制剂。本发明提供了这样的药物制剂，其中二氢吡啶钙通道阻断剂和血管紧张素-2受体阻断剂分别包含在每个隔室中并且其释放受到控制。由于制剂的每个不同区室中所含的每种不同药物在不同时间释放，本发明的药物制剂使药物之间的拮抗作用和副作用最小化，并使药物的特定作用最大化。通过本发明的两种药物之间的特定组合的药物制剂与单独施用每种药物或简单联合施用药物相比，在治疗或预防疾病方面具有显着的良好效果。

6. 发明申请

WO2009104916A3 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009104916A3
公开(公告)日：2009-11-05
申请号：PCT/KR2009000803
申请日：2009-02-21
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
IPC分类号： A61K9/52 , A61K9/22 , A61K9/48 , A61K9/50 , A61K31/00
CPC分类号： A61K9/2866 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/2095 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical formulation, which comprises a pre-release portion containing HMG-CoA (hydroxymethylglutaryl-CoA) reductase as a pharmacologically active component, and a sustained-release portion containing bis-dihydropyridine-class calcium-channel blocker as a pharmacologically active component. The formulation of the invention offers synergy effects through co-administration of the bis-dihydropyridine-class calcium-channel blocker/HMG-CoA (hydroxymethylglutaryl-CoA) reductase, and induces the time-dependent absorption, metabolism and mechanism of individual drug through the controlled release to avoid competitive antagonistic interactions between drugs, thus maximizing effects of each pharmacologically active component while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once per day.
摘要翻译：本发明提供药物制剂，其包含含有作为药理学活性成分的HMG-CoA（羟甲基戊二酰-CoA）还原酶的预释放部分和含有作为药理活性成分的双 - 二氢吡啶类钙通道阻断剂的缓释部分零件。本发明的制剂通过共同施用双 - 二氢吡啶类钙通道阻断剂/ HMG-CoA（羟甲基戊二酰-CoA）还原酶提供协同作用，并诱导单个药物通过的时间依赖性吸收，代谢和机理以避免药物之间的竞争性拮抗作用，从而最大化每种药理活性成分的作用，同时使副作用例如肌病风险最小化，并且通过每天服用一次片剂大大增加患者的顺应性。

7. 发明申请

WO2009127922A2 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127922A2
公开(公告)日：2009-10-22
申请号：PCT/IB2009000331
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/44 , A61K47/38 , A61P9/00
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation containing an immediate-release compartment and an extended-release compartment. The immediate-release compartment comprises a statin lipid-lowering drug, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient and the extended-release compartment contains a dihydropyridine calcium channel blocker, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient. The combined formulation of immediate-release, statin lipid-lowering drug and extended-release dihydropyridine calcium channel blocker, is pharmacologically, clinically, scientifically, and economically more useful than the single formulation of each of the drugs or a simple combination of the drugs, in preventing and treating cardiovascular disease, cardiopulmonary disease, pulmonary disease, or kidney disease in patients with metabolic syndrome and insulin resistance and patients with diabetes or suspected prediabetes. médicamentsThe formulation of the present invention allows different release times for the statin lipid-lowering drug and the dihydropyridine calcium channel blocker, and thus prevents mutual antagonism and side effects between the two drugs, and provides easy administration for patients simultaneously taking the two drugs simultaneously.
摘要翻译：本发明提供了含有速释隔室和缓释隔室的药物制剂。速释隔室包含作为药理活性成分的他汀类降脂药，其异构体或其药学上可接受的盐，并且缓释室包含二氢吡啶类钙通道阻断剂，其异构体或其药学上可接受的盐，作为药理学有效成分。速释他汀类降脂药和缓释二氢吡啶钙通道阻滞剂的组合制剂在药理学，临床，科学和经济上比每种药物的单一制剂或药物的简单组合更有用，用于预防和治疗代谢综合征和胰岛素抵抗患者中的心血管疾病，心肺疾病，肺病或肾病以及糖尿病或怀疑前驱糖尿病患者。本发明的制剂允许他汀类降脂药和二氢吡啶类钙通道阻滞剂的释放时间不同，从而防止两种药物之间的相互拮抗和副作用，并且为同时服用两种药物的患者提供了容易的给药。

8. 发明申请

WO2009104916A2 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009104916A2
公开(公告)日：2009-08-27
申请号：PCT/KR2009000803
申请日：2009-02-21
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
IPC分类号： A61K9/52
CPC分类号： A61K9/2866 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/2095 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical formulation, which comprises a pre-release portion containing HMG-CoA (hydroxymethylglutaryl-CoA) reductase as a pharmacologically active component, and a sustained-release portion containing bis-dihydropyridine-class calcium-channel blocker as a pharmacologically active component. The formulation of the invention offers synergy effects through co-administration of the bis-dihydropyridine-class calcium-channel blocker/HMG-CoA (hydroxymethylglutaryl-CoA) reductase, and induces the time-dependent absorption, metabolism and mechanism of individual drug through the controlled release to avoid competitive antagonistic interactions between drugs, thus maximizing effects of each pharmacologically active component while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once per day.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的HMG-CoA（羟甲基戊二酰-CoA）还原酶的预释放部分和含有双 - 二氢吡啶类钙通道阻断剂作为药理活性的缓释部分零件。本发明的制剂通过双 - 二氢吡啶类钙通道阻断剂/ HMG-CoA（羟甲基戊二酰辅酶A）还原酶的共同给药提供了协同效应，并且引起了单个药物的时间依赖性吸收，代谢和机制控制释放以避免药物之间的竞争性拮抗相互作用，从而最大化每种药理活性成分的作用，同时尽量减少副作用，例如肌病的风险，并且通过每天服用一片药物来显着增加患者的依从性。

9. 发明申请

WO2009127974A3 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127974A3
公开(公告)日：2010-03-25
申请号：PCT/IB2009006277
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/40 , A61K31/44 , A61K47/38 , A61P9/00 , A61P13/12
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation comprising: an early release portion comprising as a pharmaceutical active ingredient a statin-based hypolipidic agent, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a slow release portion comprising as a pharmaceutical active ingredient a dihydropyridine-based calcium channel blocking agent, an isomer thereof, or a pharmaceutically acceptable salt thereof. When compared with a single formulation of each of the drugs or a simple combination formulation of the drugs, the pharmaceutical formulation according to the present invention comprising an early release portion comprising a statin-based hypolipidic agent and a slow release portion comprising a dihydropyridine-based calcium channel blocking agent is pharmaceutically, scientifically, and economically very useful in preventing or treating cardiovascular disease, pulmonary heart disease, pulmonary disease, or kidney disease of patients who have a metabolic syndrome, insulin resistance, diabetes, or prediabetes. The formulation of the present invention is effective in preventing antagonistic and side effects between the drugs by making the dissolution rate of the statin-based hypolipidic agent different from that of the dihydropyridine-based calcium channel blocking agent, and in facilitating patient compliance in taking the drugs by administering the two different drugs simultaneously.
摘要翻译：本发明提供一种药物制剂，其包含：早期释放部分，其包含作为药物活性成分的基于他汀类的降血糖剂，其异构体或其药学上可接受的盐; 以及缓释部分，其包含基于二氢吡啶的钙通道阻断剂，其异构体或其药学上可接受的盐作为药物活性成分。当与药物的单一制剂或药物的简单组合制剂相比时，根据本发明的药物制剂包含早期释放部分，其包含基于他汀类的降血脂药和包含基于二氢吡啶的缓释部分钙通道阻断剂在预防或治疗具有代谢综合征，胰岛素抵抗，糖尿病或糖尿病前期的患者的心血管疾病，肺心病，肺部疾病或肾脏疾病方面在药学，科学和经济上非常有用。本发明的制剂通过使基于他汀类的降血糖剂与二氢吡啶类钙通道阻断剂的溶解速率不同而使药物的拮抗作用和副作用有效，并且为了便于患者服用药物同时服用两种不同药物。

10. 发明申请

WO2009151295A2 PHARMACEUTICAL FORMULATION COMPRISING AZELNIDIPINE AND HMG-COA REDUCTASE INHIBITOR OR ANGIOTENSIN II RECEPTOR BLOCKER 审中-公开
标题翻译：包含AZELNIDIPINE和HMG-COA还原酶抑制剂或血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009151295A2
公开(公告)日：2009-12-17
申请号：PCT/KR2009003158
申请日：2009-06-12
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , JANG SEOK YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , JANG SEOK YOUNG
IPC分类号： A61K9/22
CPC分类号： A61K31/4427 , A61K45/06
摘要： Disclosed is a controlled-release pharmaceutical formulation comprising azelnidipine and HMG-CoA reductase inhibitor or an angiotensin II receptor blocker, wherein as it takes a different amount of time to exhibit a pharmacological effect of each individual ingredient of the pharmaceutical formulation in a human body, each of the ingredients can be control-released at a specific rate to exhibit the optimum effect on absorption in the human body. The pharmaceutical formulation of the present invention is highly effective in treating hypertension and preventing its complications in persons having a so-called metabolic syndrome, which is present as a complex of hyperlipidemia, coronary artery disease, heart disease, kidney disease or cerebrovascular disease, etc., wherein, by increasing patient compliance, the impact on external factors can also be maximized.
摘要翻译：本发明公开了一种包含氮卓尼地平和HMG-CoA还原酶抑制剂或血管紧张素II受体阻断剂的控释药物制剂，其中，由于需要不同的时间量以显示药物制剂在人体中的各个成分的药理作用，可以以特定速率控制每种成分，以对人体的吸收表现出最佳效果。本发明的药物制剂在高血压，冠状动脉疾病，心脏病，肾脏疾病或脑血管病等复合物存在的所谓代谢综合征患者中治疗高血压和预防其并发症是非常有效的。其中，通过增加患者依从性，也可以最大限度地发挥对外部因素的影响。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式